Oct 21 (Reuters) - Catalent ( CTLT ) president and CEO

Alessandro Maselli said on Monday he will continue to lead the

contract drugmaker after it is acquired by Novo Holdings, the

controlling shareholder of weight-loss drug manufacturer Novo

Nordisk.

Maselli's open letter comes on the back of increased

criticism regarding Novo Holding's acquisition of Catalent ( CTLT ) that

could threaten competition in weight-loss drugs and cutting-edge

gene therapies.

(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini

Ganguli)